20200316 2020covid interactionsummary_web_2020_mar12

20200316 2020covid interactionsummary_web_2020_mar12

• 1.
  Liverpool Drug InteractionsGroup Charts updated 12 March 2020 Page 1 of 4 Please check www.covid19-druginteractions.org for updates. Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers. Key to abbreviations DRV/c Darunavir/cobicistat CLQ Chloroquine LPV/r Lopinavir/ritonavir NITA Nitazoxanide RDV Remdesivir RBV Ribavirin FAVI Favipiravir Key to symbols  These drugs should not be coadministered  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required  No clinically significant interaction expected © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. Interactions with Experimental COVID-19 Therapies DRV/c LPV/r RDV FAVI CLQ NITA RBV Anaesthetics & Muscle Relaxants Alcuronium        Bupivacaine        Cisatracurium        Desflurane        Dexmedetomidine        Enflurane        Ephedrine        Etidocaine        Halothane        Isoflurane        Ketamine        Minaxolone        Nitrous oxide        Propofol        Rocuronium        Sevoflurane        Sufentanil        Suxamethonium (succinylcholine)        Tetracaine        Thiopental        Tizanidine        Vecuronium        Analgesics Alfentanil        Aspirin        Buprenorphine        Celecoxib        Codeine        Dextropropoxyphene        Diamorphine (diacetylmorphine)        Diclofenac        Dihydrocodeine        Fentanyl        Hydrocodone        Hydromorphone        Ibuprofen        Mefenamic acid        Methadone        Morphine        Naproxen        Nimesulide        Oxycodone        Paracetamol (Acetaminophen)        Pethidine (Meperidine)        Piroxicam        Remifentanil        Tapentadol        Tramadol        Antiarrhythmics Amiodarone        Bepridil        Disopyramide        Dofetilide        Flecainide        Lidocaine (Lignocaine)        Mexiletine        Propafenone        Quinidine        DRV/c LPV/r RDV FAVI CLQ NITA RBV Antibacterials Amikacin        Amoxicillin        Ampicillin        Azithromycin        Bedaquiline        Capreomycin        Cefalexin        Cefazolin        Cefixime        Cefotaxime        Ceftazidime        Ceftriaxone        Chloramphenicol        Ciprofloxacin        Clarithromycin        Clavulanic acid        Clindamycin        Clofazimine        Cloxacillin        Cycloserine        Dapsone        Delamanid        Doxycycline        Ertapenem        Erythromycin        Ethambutol        Ethionamide        Flucloxacillin        Gentamicin        Imipenem/Cilastatin        Isoniazid        Kanamycin        Levofloxacin        Linezolid        Meropenem        Metronidazole        Moxifloxacin        Nitrofurantoin        Ofloxacin        Para-aminosalicylic acid        Penicillins        Piperacillin        Pyrazinamide        Rifabutin        Rifampicin        Rifapentine        Rifaximin        Spectinomycin        Streptomycin        Sulfadiazine        Tazobactam        Telithromycin        Tetracyclines        Tinidazole        Trimethoprim/Sulfamethoxazole        Vancomycin       
• 2.
  Liverpool Drug InteractionsGroup Charts updated 12 March 2020 Page 2 of 4 Please check www.covid19-druginteractions.org for updates. Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers. Key to abbreviations DRV/c Darunavir/cobicistat CLQ Chloroquine LPV/r Lopinavir/ritonavir NITA Nitazoxanide RDV Remdesivir RBV Ribavirin FAVI Favipiravir Key to symbols  These drugs should not be coadministered  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required  No clinically significant interaction expected © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. Interactions with Experimental COVID-19 Therapies DRV/c LPV/r RDV FAVI CLQ NITA RBV Anti-coagulant, Anti-platelet and Fibrinolytic Acenocoumarol        Apixaban        Argatroban        Aspirin (anti-platelet)        Betrixaban        Clopidogrel        Dabigatran        Dalteparin        Dipyridamole        Edoxaban        Eltrombopag        Enoxaparin        Fondaparinux        Heparin        Phenprocoumon        Prasugrel        Rivaroxaban        Streptokinase        Ticagrelor        Warfarin        Antidepressants Agomelatine        Amitriptyline        Bupropion        Citalopram        Clomipramine        Desipramine        Doxepin        Duloxetine        Escitalopram        Fluoxetine        Fluvoxamine        Imipramine        Lithium        Maprotiline        Mianserin        Milnacipran        Mirtazapine        Nefazodone        Nortriptyline        Paroxetine        Phenelzine        Reboxetine        Sertraline        St John’s wort        Tranylcypromine        Trazodone        Trimipramine        Venlafaxine        Vortioxetine        DRV/c LPV/r RDV FAVI CLQ NITA RBV Anti-diabetics Acarbose        Canagliflozin        Dapagliflozin        Dulaglutide        Empagliflozin        Exanatide        Glibenclamide (Glyburide)        Gliclazide        Glimepiride        Glipizide        Insulin        Linagliptin        Liraglutide        Metformin        Nateglinide        Pioglitazone        Repaglinide        Rosiglitazone        Saxagliptin        Sitagliptin        Tolbutamide        Vildagliptin        Antipsychotics/Neuroleptics Amisulpride        Aripiprazole        Asenapine        Chlorpromazine        Clozapine        Fluphenazine        Haloperidol        Iloperidone        Levomepromazine        Olanzapine        Paliperidone        Perazine        Periciazine        Perphenazine        Pimozide        Pipotiazine        Quetiapine        Risperidone        Sulpiride        Thioridazine        Tiapride        Ziprasidone        Zotepine        Zuclopenthixol        Antivirals Darunavir/cobicistat        Lopinavir/ritonavir        Remdesivir        Favipiravir        Chloroquine        Nitazoxanide        Ribavirin        Oseltamivir       
• 3.
  Liverpool Drug InteractionsGroup Charts updated 12 March 2020 Page 3 of 4 Please check www.covid19-druginteractions.org for updates. Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers. Key to abbreviations DRV/c Darunavir/cobicistat CLQ Chloroquine LPV/r Lopinavir/ritonavir NITA Nitazoxanide RDV Remdesivir RBV Ribavirin FAVI Favipiravir Key to symbols  These drugs should not be coadministered  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required  No clinically significant interaction expected © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. Interactions with Experimental COVID-19 Therapies DRV/c LPV/r RDV FAVI CLQ NITA RBV Anxiolytics/Hypnotics/Sedatives Alprazolam        Bromazepam        Buspirone        Chlordiazepoxide        Clobazam        Clorazepate        Diazepam        Estazolam        Flunitrazepam        Flurazepam        Hydroxyzine        Lorazepam        Lormetazepam        Midazolam (oral)        Midazolam (parenteral)        Oxazepam        Temazepam        Triazolam        Zaleplon        Zolpidem        Zopiclone        Beta Blockers Atenolol        Bisoprolol        Carvedilol        Metoprolol        Nebivolol        Oxprenolol        Pindolol        Propranolol        Timolol        Bronchodilators Aclidinium bromide        Aminophylline        Formoterol        Glycopyrronium bromide        Indacaterol        Ipratropium bromide        Montelukast        Olodaterol        Roflumilast        Salbutamol        Salmeterol        Theophylline        Tiotropium bromide        Umeclidinium bromide        Vilanterol        Calcium Channel Blockers Amlodipine        Diltiazem        Felodipine        Nicardipine        Nifedipine        Nisoldipine        Nitrendipine        Verapamil        DRV/c LPV/r RDV FAVI CLQ NITA RBV Contraceptives/HRT Desogestrel (COC)        Desogestrel (POP)        Drospirenone (COC)        Drospirenone (HRT)        Dydrogesterone (HRT)        Estradiol        Ethinylestradiol        Etonogestrel (implant)        Etonogestrel (vaginal ring)        Gestodene (COC)        Levonorgestrel (COC)        Levonorgestrel (emergencycontrac.)        Levonorgestrel (HRT)        Levonorgestrel (implant)        Levonorgestrel (IUD)        Levonorgestrel (POP)        Medroxyprogesterone (depot inj.)        Medroxyprogesterone (oral)        Norelgestromin (patch)        Norethisterone (COC)        Norethisterone (HRT)        Norethisterone (IM depot)        Norethisterone(POP)        Norgestimate (COC)        Norgestrel (COC)        Norgestrel (HRT)        Ulipristal        Gastrointestinal Agents Alosetron        Antacids        Bisacodyl        Cimetidine        Cisapride        Esomeprazole        Famotidine        Lactulose        Lansoprazole        Loperamide        Mesalazine        Omeprazole        Pantoprazole        Prucalopride        Rabeprazole        Ranitidine        Senna        Gastrointestinal Agents (anti-emetics) Aprepitant        Dolasetron        Domperidone        Dronabinol        Granisetron        Metoclopramide        Ondansetron        Prochlorperazine       
• 4.
  Liverpool Drug InteractionsGroup Charts updated 12 March 2020 Page 4 of 4 Please check www.covid19-druginteractions.org for updates. Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. No recommendation to use experimental therapy for COVID-19 is made. Drug interaction data for many agents are limited or absent; therefore, risk-benefit assessment for any individual patient rests with prescribers. Key to abbreviations DRV/c Darunavir/cobicistat CLQ Chloroquine LPV/r Lopinavir/ritonavir NITA Nitazoxanide RDV Remdesivir RBV Ribavirin FAVI Favipiravir Key to symbols  These drugs should not be coadministered  Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required  No clinically significant interaction expected © Liverpool Drug Interaction Group, University of Liverpool, Pharmacology Research Labs, 1st Floor Block H, 70 Pembroke Place, LIVERPOOL, L69 3GF We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law. Interactions with Experimental COVID-19 Therapies DRV/c LPV/r RDV FAVI CLQ NITA RBV Hypertension / Heart Failure Agents Aliskiren        Ambrisentan        Amiloride        Benazepril        Bendroflumethiazide        Bosentan        Candesartan        Captopril        Chlortalidone        Cilazapril        Clonidine        Digoxin        Dopamine        Doxazosin        Enalapril        Eplerenone        Epoprostenol        Eprosartan        Fosinopril        Furosemide        Hydralazine        Hydrochlorothiazide        Iloprost        Indapamide        Irbesartan        Isosorbide dinitrate        Ivabradine        Labetalol        Lacidipine        Lercanidipine        Lisinopril        Losartan        Macitentan        Methyldopa        Metolazone        Moxonidine        Olmesartan        Perindopril        Prazosin        Quinapril        Ramipril        Ranolazine        Riociguat        Sacubitril        Selexipag        Sildenafil (PAH)        Sodium nitroprusside        Spironolactone        Tadalafil (PAH)        Telmisartan        Terazosin        Torasemide        Trandolapril        Treprostinil        Valsartan        Xipamide        DRV/c LPV/r RDV FAVI CLQ NITA RBV Immunosuppressants Adalimumab        Anti-thymocyte globulin        Azathioprine        Basiliximab        Belatacept        Ciclosporin        Mycophenolate        Sirolimus        Tacrolimus        Inotropes & Vasopressors Adrenaline (Epinephrine)        Dobutamine        Noradrenaline        Vasopressin        Lipid Lowering Agents Atorvastatin        Bezafibrate        Clofibrate        Evolocumab        Ezetimibe        Fenofibrate        Fish oils        Fluvastatin        Gemfibrozil        Lovastatin        Pitavastatin        Pravastatin        Rosuvastatin        Simvastatin        Steroids Beclometasone        Betamethasone        Budesonide        Ciclesonide        Clobetasol        Dexamethasone        Fludrocortisone        Flunisolide        Fluocinolone        Fluticasone        Hydrocortisone (oral)        Hydrocortisone (topical)        Megestrol acetate        Methylprednisolone        Mometasone        Nandrolone        Oxandrolone        Prednisolone        Prednisone        Stanazolol        Testosterone        Triamcinolone       